Verinata Enters Supply Deal with Illumina for Prenatal Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Verinata Health today said that it has entered into a three-year supply deal with Illumina, under which it will purchase sequencing instruments and consumables for use in commercializing its prenatal diagnostics offerings.

Verinata is developing tests for detecting multiple aneuploidies. The San Carlos, Calif.-based firm said that in addition to the supply deal it will collaborate with Illumina on gaining regulatory approval for the testing service.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.